These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy. Mejstríková E; Kalina T; Trka J; Starý J; Hrusák O Leukemia; 2005 Jun; 19(6):1092-4. PubMed ID: 15830012 [No Abstract] [Full Text] [Related]
11. Upfront use of gemtuzumab ozogamicin in young children with CD33-positive AML. Sayar D; Burstein Y; Bielorai B; Toren A; Dvir R Pediatr Blood Cancer; 2010 Jul; 55(1):183-5. PubMed ID: 20310000 [TBL] [Abstract][Full Text] [Related]
12. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Raponi S; De Propris MS; Intoppa S; Milani ML; Vitale A; Elia L; Perbellini O; Pizzolo G; Foá R; Guarini A Leuk Lymphoma; 2011 Jun; 52(6):1098-107. PubMed ID: 21348573 [TBL] [Abstract][Full Text] [Related]
14. Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT. Swords R; Hayden PJ; Molloy K; Lawlor M; Browne PV; Murphy PT Eur J Haematol; 2004 Dec; 73(6):450-1. PubMed ID: 15522070 [No Abstract] [Full Text] [Related]
15. New developments in the treatment of acute myeloid leukemia. Radich J; Sievers E Oncology (Williston Park); 2000 Nov; 14(11A):125-31. PubMed ID: 11195406 [TBL] [Abstract][Full Text] [Related]
16. FDA approves antibody-directed cytotoxic agent for acute myeloid leukemia. Miller JL Am J Health Syst Pharm; 2000 Jul; 57(13):1202, 1204. PubMed ID: 10902059 [No Abstract] [Full Text] [Related]
17. Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm. Wong ET Expert Opin Pharmacother; 2005 Jun; 6(7):1107-14. PubMed ID: 15957965 [TBL] [Abstract][Full Text] [Related]
18. Phase III trial of a humanized anti-CD33 antibody (HuM195) in patients with relapsed or refractory acute myeloid leukemia. Gibson AD Clin Lymphoma; 2002 Jun; 3(1):18-9. PubMed ID: 12141950 [No Abstract] [Full Text] [Related]
19. Monoclonal antibody therapy of APL. Maslak PG; Jurcic JG; Scheinberg DA Curr Top Microbiol Immunol; 2007; 313():205-19. PubMed ID: 17217045 [TBL] [Abstract][Full Text] [Related]
20. Successful use of gemtuzumab ozogamicin in a child with relapsed CD33-positive acute lymphoblastic leukaemia. Cotter M; Rooney S; O'Marcaigh A; Smith OP Br J Haematol; 2003 Aug; 122(4):687-8. PubMed ID: 12899727 [No Abstract] [Full Text] [Related] [Next] [New Search]